Approval · Notice of Compliance 30191 · 2023
NAT-POMALIDOMIDE: Notice of Compliance 30191
Issued February 22, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30191
- Date
- February 22, 2023
- Company
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- POMALYST (Celgene Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAT-POMALIDOMIDE | 02506394 | Marketed |
| NAT-POMALIDOMIDE | 02506408 | Marketed |
| NAT-POMALIDOMIDE | 02506416 | Marketed |
| NAT-POMALIDOMIDE | 02506424 | Marketed |
Medicinal ingredients
- POMALIDOMIDE 1 MG per CAP
- POMALIDOMIDE 2 MG per CAP
- POMALIDOMIDE 3 MG per CAP
- POMALIDOMIDE 4 MG per CAP